Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.4B | $4B | $4.5B | $994.2M | $1.2B | |
| Gross Profit | $2.2B | $2.4B | $2.7B | $593.8M | $747.4M | |
| Operating Income | $506.2M | $628M | $777.7M | $152M | $242.5M | |
| EBITDA | $676M | $840.4M | $1B | $207.3M | $306.1M | |
| Diluted EPS | $0.90 | $1.67 | $1.80 | $0.34 | $0.70 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.7B | $3.4B | $4.7B | $4.3B | $5.2B | |
| Total Assets | $4.8B | $4.9B | $6.6B | $6.4B | $7.5B | |
| Current Liabilities | $734.9M | $900.5M | $1.7B | $1.7B | $3.3B | |
| Total Liabilities | $2.6B | $3.1B | $4.3B | $4.4B | $4.8B | |
| Total Equity | $2.1B | $1.8B | $2.3B | $2B | $2.7B | |
| Total Debt | $1.9B | $2.1B | $2.7B | $2.6B | $2.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $747.4M | $821.7M | $1.4B | $199.5M | $659.9M | |
| Cash From Investing | -$1.1B | $511.1M | -$74.3M | $210.3M | $192.8M | |
| Cash From Financing | $312.3M | -$1.4B | -$165.8M | -$736.5M | -$175M | |
| Free Cash Flow | $499.8M | $535M | $1.1B | $88.3M | $579.4M | |
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.
In the current month, DXCM has received 20 Buy ratings 4 Hold ratings, and 0 Sell ratings. The DXCM average analyst price target in the past 3 months is $85.27.
According to analysts, the consensus estimate is that DexCom, Inc. share price will rise to $85.27 per share over the next 12 months.
Analysts are divided on their view about DexCom, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that DexCom, Inc. is a Sell and believe this share price will drop from its current level to $68.00.
The price target for DexCom, Inc. over the next 1-year time period is forecast to be $85.27 according to 24 Wall Street analysts, 20 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for DexCom, Inc. is a Buy. 20 of 24 analysts rate the stock a Buy at this time.
You can purchase shares of DexCom, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase DexCom, Inc. shares.
DexCom, Inc. was last trading at $69.48 per share. This represents the most recent stock quote for DexCom, Inc.. Yesterday, DexCom, Inc. closed at $67.65 per share.
In order to purchase DexCom, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $3.9T
P/E Ratio: 36x
Market Cap: $3.8T
P/E Ratio: 39x
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Innodata, Inc. [INOD] is up 4.84% over the past day.
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.